The European regulatory environment of rna-based vaccines

Methods in Molecular Biology

Volumn 1499, Issue , 2017, Pages 203-222

  Hinz, Thomas ^a   Kallen, Kajo ^b   Britten, Cedrik M ^c   Flamion, Bruno ^d   Granzer, Ulrich ^e   Hoos, Axel ^f   Huber, Christoph ^g   Khleif, Samir ^h   Kreiter, Sebastian ^g   Rammensee, Hans Georg ^i,j   Sahin, Ugur ^k,l,p   Singh Jasuja, Harpreet ^m   Türeci, Özlem ⁿ   Kalinke, Ulrich ^o  

^a PAUL EHRLICH INSTITUT   (Germany)

^b Kallen Consulting   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

^d University of Namur   (Belgium)

^e Granzer   (Germany)

^f GLAXOSMITHKLINE   (United States)

^g Association for Cancer Immunotherapy   (Germany)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j German Cancer Consortium (DKTK)   (Germany)

^k JOHANNES GUTENBERG UNIVERSITY   (Germany)

^l BIONTECH AG   (Germany)

^m IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

ⁿ Cluster for individualized Immune Intervention ^*  (Germany)

^o INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^p Research Center for Immunotherapy (FZI)   (Germany)

more..

Author keywords

Advanced therapy medicinal products (ATMP); Anticancer vaccination; Genetically modified medicinal products; mRNA; Preventive and therapeutic approaches; Regulatory framework in the EU; Vaccination against infectious disease; Vaccines

Indexed keywords

MESSENGER RNA; MESSENGER RNA VACCINE; RNA VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; ANTIGEN; CANCER VACCINE;

ADVISORY COMMITTEE; ALLERGY; CANCER IMMUNIZATION; DRUG APPROVAL; DRUG LEGISLATION; DRUG MARKETING; EUROPEAN; HUMAN; IN VIVO STUDY; INFECTION; MALIGNANT NEOPLASTIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; RNA IMMUNIZATION; ANIMAL; EUROPE; GENE THERAPY; IMMUNOLOGY; NEOPLASM; PROCEDURES;

ANIMALS; ANTIGENS; CANCER VACCINES; EUROPE; GENETIC THERAPY; HUMANS; NEOPLASMS; RNA, MESSENGER;

EID: 85007163158     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-6481-9_13     Document Type: Chapter

References (67)

1. Matthaei H, Nirenberg MW (1961) The dependence of cell-free protein synthesis in E. coli upon RNA prepared from ribosomes. Biochem Biophys Res Commun 4:404-408
2. Matthaei JH, Nirenberg MW (1961) Characteristics and stabilization of DNAase-sensitive protein synthesis in E.coli extracts. Proc Natl Acad Sci U S A 47:1580-1588
3. Wolff JA, Malone RW, Williams P et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468
4. Tang DC, DeVit M, Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356:152-154
5. Martinon F, Krishnan S, Lenzen G et al (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719-1722
6. Conry RM, LoBuglio AF, Wright M et al (1995) Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55:1397-1400
7. Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1-7
8. Pascolo S (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4:1285-1294
9. Ketterer T, von der Mülbe F, Reidel L et al (2008) Method for purifying RNA on a preparative scale by means of hplc. Patent WO2008077592
10. Pardi N, Muramatsu H, Weissman D et al (2013) In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol 969:29-42
11. Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165-175
12. Holtkamp S, Kreiter S, Selmi A et al (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108:4009-4017
13. Kariko K, Muramatsu H, Welsh FA et al (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16:1833-1840
14. Kuhn AN, Diken M, Kreiter S et al (2010) Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 17:961-971
15. Kormann MS, Hasenpusch G, Aneja MK et al (2011) Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29:154-157
16. Kariko K, Muramatsu H, Keller JM et al (2012) Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 20:948-953
17. Schlake T, Thess A, Fotin-Mleczek M et al (2012) Developing mRNA-vaccine technologies. RNA Biol 9:1319-1330
18. Kallen K-J, Thess A (2014) A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2:10-31
19. Thess A, Grund S, Mui BL et al (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23:1456-1464
20. Lorenz C, Fotin-Mleczek M, Roth G et al (2011) Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 8:627-636
21. Diken M, Kreiter S, Selmi A et al (2011) Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 18:702-708
22. Sahin U, Kariko K, Tureci O (2014) mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13:759-780
23. Fotin-Mleczek M, Duchardt KM, Lorenz C et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34:1-15
24. Sebastian M, von Boehmer L, Zippelius A et al (2011) Messenger RNA vaccination in NSCLC: findings from a phase I/IIa clinical trial. J Clin Oncol 29:(suppl; abstr 2584)
25. Sebastian M, von Boehmer L, Zippelius A et al (2012) Messenger RNA vaccination and B-cell responses in NSCLC patients. J Clin Oncol 30:(suppl; abstr 2573)
26. Sebastian M, Papachristofilou A, Weiss C et al (2014) Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14:748
27. Kubler H, Scheel B, Gnad-Vogt U et al (2015) Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/ IIa study. J Immunother Cancer 3:26
28. Kreiter S, Selmi A, Diken M et al (2008) Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 180:309-318
29. Britten CM, Singh-Jasuja H, Flamion B et al (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31:880-882
30. Castle JC, Kreiter S, Diekmann J et al (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72:1081-1091
31. Castle JC, Loewer M, Boegel S et al (2014) Mutated tumor alleles are expressed according to their DNA frequency. Sci Rep 4:4743
32. Kreiter S, Vormehr M, van de Roemer N et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:692-696
33. Bonehill A, Tuyaerts S, Van Nuffel AM et al (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170-1180
34. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ et al (2012) Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 18:5460-5470
35. Wilgenhof S, Corthals J, Van Nuffel AM et al (2015) Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 64:381-388
36. Wilgenhof S, Van Nuffel AMT, Benteyn D et al (2013) Phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686-2693
37. Petsch B, Schnee M, Vogel AB et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30:1210-1216
38. Geall AJ, Verma A, Otten GR et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109:14604-14609
39. Lazzaro S, Giovani C, Mangiavacchi S et al (2015) CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology 146:312-326
40. Brazzoli M, Magini D, Bonci A et al (2015) Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol. doi:10.1128/JVI.01786-15
41. Bogers WM, Oostermeijer H, Mooij P et al (2015) Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211:947-955
42. Hekele A, Bertholet S, Archer J et al (2013) Rapidly produced SAMH vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2:e52
43. Ulmer JB, Mansoura MK, Geall AJ (2015) Vaccines ‘on demand’: science fiction or a future reality. Expert Opin Drug Discov 10(2):101-106
44. Boisguerin V, Castle JC, Loewer M et al (2014) Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. Br J Cancer 111:1469-1475
45. Geall AJ, Mandl CW, Ulmer JB (2013) RNA: the new revolution in nucleic acid vaccines. Semin Immunol 25:152-159
46. Roesler E, Weiss R, Weinberger EE et al (2009) Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 124:1070-1077
47. Weiss R, Scheiblhofer S, Thalhamer J (2014) Allergens are not pathogens: why immunization against allergy differs from vaccination against infectious diseases. Hum Vaccin Immunother 10:703-707
48. Zangi L, Lui KO, von Gise A et al (2013) Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 31:898-907
49. EU, Regulation (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC
50. EC, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency
51. EC, Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/ EC and Regulation (EC) No 726/2004
52. EU, COMMISSION DIRECTIVE 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products
53. EMA, Reflection paper on classification of advanced therapy medicinal products. 20 June 2014. EMA/CAT/600280/2010 Rev.1. Committee for Advanced Therapies (CAT)
54. EMA, Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials. EMA/CHMP/534898/2008
55. EU, Guidelines to Good Manufacturing Practice. Medicinal Products for Human and Veterinary Use. Annex 13. Investigational Medicinal Products
56. ICH, Harmonised tripartite guideline for good clinical practice E6(R1)
57. EU, Volume 2B. Notice to applicants. Medicinal products for human use
58. EMA, Guideline on the risk-based approach according to annex I, part IV of Directive 2001/83/EC applied to advanced therapy medicinal products
59. EMA, Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. EMA/CAT/80183/2014
60. EMA, Guideline on human cell-based medicinal products. EMEA/CHMP/410869/2006
61. EMA, Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. EMA/CAT/ GTWP/671639/2008
62. EU, Good manufacturing practice. Medicinal products for human and veterinary use. Part II: basic requirements for active substances used as starting materials
63. EMA, Note for guidance on preclinical pharmacological and toxicological testing of vaccines. CPMP/SWP/465/95
64. EMA, Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. ICH M(3)
65. EMA, Guideline on the evaluation of anticancer medicinal products in man. EMA/ CHMP/205/95/Rev.4
66. EMA, Guideline on clinical evaluation of new vaccines. EMEA/CHMP/ VWP/164653/2005
67. FDA, Guidance for Industry. Clinical Considerations for Therapeutic Cancer Vaccines